<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36810162</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">2332-7812</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Neurology(R) neuroimmunology &amp; neuroinflammation</Title><ISOAbbreviation>Neurol Neuroimmunol Neuroinflamm</ISOAbbreviation></Journal><ArticleTitle>Autocrine TNF-&#x3b1; Increases Penetration of Myelin-Associated Glycoprotein Antibodies Across the Blood-Nerve Barrier in Anti-MAG Neuropathy.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e200086</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1212/NXI.0000000000200086</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES">Deposition of myelin-associated glycoprotein (MAG) immunoglobulin M (IgM) antibodies in the sural nerve is a key feature in anti-MAG neuropathy. Whether the blood-nerve barrier (BNB) is disrupted in anti-MAG neuropathy remains elusive.We aimed to evaluate the effect of sera from anti-MAG neuropathy at the molecular level using our in vitro human BNB model and observe the change of BNB endothelial cells in the sural nerve of anti-MAG neuropathy.</AbstractText><AbstractText Label="METHODS">Diluted sera from patients with anti-MAG neuropathy (n = 16), monoclonal gammopathies of undetermined significance (MGUS) neuropathy (n = 7), amyotrophic lateral sclerosis (ALS, n = 10), and healthy controls (HCs, n = 10) incubated with human BNB endothelial cells to identify the key molecule of BNB activation using RNA-seq and a high-content imaging system, and exposed with a BNB coculture model to evaluate small molecule/IgG/IgM/anti-MAG antibody permeability.</AbstractText><AbstractText Label="RESULTS">RNA-seq and the high-content imaging system showed the significant upregulation of tumor necrosis factor (TNF-&#x3b1;) and nuclear factor-kappa B (NF-&#x3ba;B) in BNB endothelial cells after exposure to sera from patients with anti-MAG neuropathy, whereas the serum TNF-&#x3b1; concentration was not changed among the MAG/MGUS/ALS/HC groups. Sera from patients with anti-MAG neuropathy did not increase 10-kDa dextran or IgG permeability but enhanced IgM and anti-MAG antibody permeability. Sural nerve biopsy specimens from patients with anti-MAG neuropathy showed higher TNF-&#x3b1; expression levels in BNB endothelial cells and preservation of the structural integrity of the tight junctions and the presence of more vesicles in BNB endothelial cells. Neutralization of TNF-&#x3b1; reduces IgM/anti-MAG antibody permeability.</AbstractText><AbstractText Label="DISCUSSION">Sera from individuals with anti-MAG neuropathy increased transcellular IgM/anti-MAG antibody permeability via autocrine TNF-&#x3b1; secretion and NF-&#x3ba;B signaling in the BNB.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Ryota</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Clinical Neuroscience (R.S., F.S., Y.S., Y.T., Michiaki Koga, T.K.), Yamaguchi University Graduate School of Medicine, Ube; Department of Neurology (Motoi Kuwahara, S.K.), Kindai University Faculty of Medicine, Osaka; Center for Gene Research (Y.M., K.W.), Yamaguchi University, Ube, Japan; and Japan Community Health Care Organization (S.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimizu</LastName><ForeName>Fumitaka</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Clinical Neuroscience (R.S., F.S., Y.S., Y.T., Michiaki Koga, T.K.), Yamaguchi University Graduate School of Medicine, Ube; Department of Neurology (Motoi Kuwahara, S.K.), Kindai University Faculty of Medicine, Osaka; Center for Gene Research (Y.M., K.W.), Yamaguchi University, Ube, Japan; and Japan Community Health Care Organization (S.K.). fshimizu@yamaguchi-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuwahara</LastName><ForeName>Motoi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Clinical Neuroscience (R.S., F.S., Y.S., Y.T., Michiaki Koga, T.K.), Yamaguchi University Graduate School of Medicine, Ube; Department of Neurology (Motoi Kuwahara, S.K.), Kindai University Faculty of Medicine, Osaka; Center for Gene Research (Y.M., K.W.), Yamaguchi University, Ube, Japan; and Japan Community Health Care Organization (S.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mizukami</LastName><ForeName>Yoichi</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-3290-0754</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology and Clinical Neuroscience (R.S., F.S., Y.S., Y.T., Michiaki Koga, T.K.), Yamaguchi University Graduate School of Medicine, Ube; Department of Neurology (Motoi Kuwahara, S.K.), Kindai University Faculty of Medicine, Osaka; Center for Gene Research (Y.M., K.W.), Yamaguchi University, Ube, Japan; and Japan Community Health Care Organization (S.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Clinical Neuroscience (R.S., F.S., Y.S., Y.T., Michiaki Koga, T.K.), Yamaguchi University Graduate School of Medicine, Ube; Department of Neurology (Motoi Kuwahara, S.K.), Kindai University Faculty of Medicine, Osaka; Center for Gene Research (Y.M., K.W.), Yamaguchi University, Ube, Japan; and Japan Community Health Care Organization (S.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maeda</LastName><ForeName>Toshihiko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Clinical Neuroscience (R.S., F.S., Y.S., Y.T., Michiaki Koga, T.K.), Yamaguchi University Graduate School of Medicine, Ube; Department of Neurology (Motoi Kuwahara, S.K.), Kindai University Faculty of Medicine, Osaka; Center for Gene Research (Y.M., K.W.), Yamaguchi University, Ube, Japan; and Japan Community Health Care Organization (S.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sano</LastName><ForeName>Yasuteru</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Clinical Neuroscience (R.S., F.S., Y.S., Y.T., Michiaki Koga, T.K.), Yamaguchi University Graduate School of Medicine, Ube; Department of Neurology (Motoi Kuwahara, S.K.), Kindai University Faculty of Medicine, Osaka; Center for Gene Research (Y.M., K.W.), Yamaguchi University, Ube, Japan; and Japan Community Health Care Organization (S.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takeshita</LastName><ForeName>Yukio</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0314-550X</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology and Clinical Neuroscience (R.S., F.S., Y.S., Y.T., Michiaki Koga, T.K.), Yamaguchi University Graduate School of Medicine, Ube; Department of Neurology (Motoi Kuwahara, S.K.), Kindai University Faculty of Medicine, Osaka; Center for Gene Research (Y.M., K.W.), Yamaguchi University, Ube, Japan; and Japan Community Health Care Organization (S.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koga</LastName><ForeName>Michiaki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Clinical Neuroscience (R.S., F.S., Y.S., Y.T., Michiaki Koga, T.K.), Yamaguchi University Graduate School of Medicine, Ube; Department of Neurology (Motoi Kuwahara, S.K.), Kindai University Faculty of Medicine, Osaka; Center for Gene Research (Y.M., K.W.), Yamaguchi University, Ube, Japan; and Japan Community Health Care Organization (S.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kusunoki</LastName><ForeName>Susumu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Clinical Neuroscience (R.S., F.S., Y.S., Y.T., Michiaki Koga, T.K.), Yamaguchi University Graduate School of Medicine, Ube; Department of Neurology (Motoi Kuwahara, S.K.), Kindai University Faculty of Medicine, Osaka; Center for Gene Research (Y.M., K.W.), Yamaguchi University, Ube, Japan; and Japan Community Health Care Organization (S.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanda</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>From the Department of Neurology and Clinical Neuroscience (R.S., F.S., Y.S., Y.T., Michiaki Koga, T.K.), Yamaguchi University Graduate School of Medicine, Ube; Department of Neurology (Motoi Kuwahara, S.K.), Kindai University Faculty of Medicine, Osaka; Center for Gene Research (Y.M., K.W.), Yamaguchi University, Ube, Japan; and Japan Community Health Care Organization (S.K.).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurol Neuroimmunol Neuroinflamm</MedlineTA><NlmUniqueID>101636388</NlmUniqueID><ISSNLinking>2332-7812</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018992">Myelin-Associated Glycoprotein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018992" MajorTopicYN="N">Myelin-Associated Glycoprotein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049428" MajorTopicYN="N">Blood-Nerve Barrier</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010523" MajorTopicYN="Y">Peripheral Nervous System Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008998" MajorTopicYN="Y">Monoclonal Gammopathy of Undetermined Significance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>22</Day><Hour>14</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36810162</ArticleId><ArticleId IdType="pmc">PMC9944621</ArticleId><ArticleId IdType="doi">10.1212/NXI.0000000000200086</ArticleId><ArticleId IdType="pii">10/3/e200086</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dalakas MC. Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies. Ther Adv Neurol Disord. 2018;11:175628561774664. doi. 10.1177/1756285617746640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756285617746640</ArticleId><ArticleId IdType="pmc">PMC5791554</ArticleId><ArticleId IdType="pubmed">29403542</ArticleId></ArticleIdList></Reference><Reference><Citation>Steck AJ, Stalder AK, Renaud S. Anti-myelin-associated glycoprotein neuropathy. Curr Opin Neurol. 2006;19(5):458-463. doi. 10.1097/01.wco.0000245368.36576.0d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.wco.0000245368.36576.0d</ArticleId><ArticleId IdType="pubmed">16969155</ArticleId></ArticleIdList></Reference><Reference><Citation>Svahn J, Petiot P, Antoine JC, et al. . Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features. J Neurol Neurosurg Psychiatry. 2018;89(5):499-505. doi. 10.1136/jnnp-2017-316715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316715</ArticleId><ArticleId IdType="pubmed">29070644</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev. 2016;10:CD002827. doi. 10.1002/14651858.CD002827.pub4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD002827.pub4</ArticleId><ArticleId IdType="pmc">PMC6457998</ArticleId><ArticleId IdType="pubmed">27701752</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalakas MC. Pathogenesis and treatment of anti-MAG neuropathy. Curr Treat Options Neurol. 2010;12(2):71-83. doi. 10.1007/s11940-010-0065-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11940-010-0065-x</ArticleId><ArticleId IdType="pubmed">20842571</ArticleId></ArticleIdList></Reference><Reference><Citation>Quarles RH. Myelin-associated glycoprotein (MAG): past, present and beyond. J Neurochem. 2007;0(0):1431-1448. doi. 10.1111/j.1471-4159.2006.04319.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.04319.x</ArticleId><ArticleId IdType="pubmed">17241126</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritz MF, Erne B, Ferracin F, Vital A, Vital C, Steck AJ. Anti-MAG IgM penetration into myelinated fibers correlates with the extent of myelin widening. Muscle Nerve. 1999;22(8):1030-1037. doi. 10.1002/(sici)1097-4598(199908)22:8&lt;1030::aid-mus4&gt;3.0.co;2-h.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(sici)1097-4598(199908)22:8&lt;1030::aid-mus4&gt;3.0.co;2-h</ArticleId><ArticleId IdType="pubmed">10417783</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabriel JM, Erne B, Bernasconi L, et al. . Confocal microscopic localization of anti-myelin-associated glycoprotein autoantibodies in a patient with peripheral neuropathy initially lacking a detectable IgM gammopathy. Acta Neuropathol. 1998;95(5):540-546. doi. 10.1007/s004010050835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004010050835</ArticleId><ArticleId IdType="pubmed">9600601</ArticleId></ArticleIdList></Reference><Reference><Citation>Monaco S, Bonetti B, Ferrari S, et al. . Complement-mediated demyelination in patients with IgM monoclonal gammopathy and polyneuropathy. N Engl J Med. 1990;322(10):649-652. doi. 10.1056/nejm199003083221002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejm199003083221002</ArticleId><ArticleId IdType="pubmed">1689461</ArticleId></ArticleIdList></Reference><Reference><Citation>Willison HJ, Trapp BD, Bacher JD, Dalakas MC, Griffin JW, Quarles RH. Demyelination induced by intraneural injection of human antimyelin-associated glycoprotein antibodies. Muscle Nerve. 1988;11:1169-1176. doi. 10.1002/mus.880111111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.880111111</ArticleId><ArticleId IdType="pubmed">2465494</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatum AH. Experimental paraprotein neuropathy, demyelination by passive transfer of human IgM anti-myelin-associated glycoprotein. Ann Neurol. 1993;33(5):502-506. doi. 10.1002/ana.410330514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410330514</ArticleId><ArticleId IdType="pubmed">7684583</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilyas AA, Gu Y, Dalakas MC, Quarles RH, Bhatt S. Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPG. J Neuroimmunol. 2008;193(1-2):87-93. doi. 10.1016/j.jneuroim.2007.10.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2007.10.025</ArticleId><ArticleId IdType="pmc">PMC2384227</ArticleId><ArticleId IdType="pubmed">18037501</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaku DA, England JD, Sumner AJ. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Brain. 1994;117(5):941-947. doi. 10.1093/brain/117.5.941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/117.5.941</ArticleId><ArticleId IdType="pubmed">7953603</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalakas MC, Papadopoulos NM. Paraproteins in the spinal fluid of patients with paraproteinemic polyneuropathies. Ann Neurol. 1984;15(6):590-593. doi. 10.1002/ana.410150612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410150612</ArticleId><ArticleId IdType="pubmed">6430213</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu RK, Ariga T, Kohriyama T, Kusunoki S, Maeda Y, Miyatani N. Autoimmune mechanisms in peripheral neuropathies. Ann Neurol. 1990;27(S1):S30-S35. doi. 10.1002/ana.410270709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410270709</ArticleId><ArticleId IdType="pubmed">2163594</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz M, Puthenparampil M, Campagnolo M, et al. . Oligoclonal IgG bands in chronic inflammatory polyradiculoneuropathies. J Neurol Neurosurg Psychiatry. 2021;92(9):969-974. doi. 10.1136/jnnp-2020-325868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-325868</ArticleId><ArticleId IdType="pubmed">33850000</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanda T, Usui S, Beppu H, Miyamoto K, Yamawaki M, Oda M. Blood-nerve barrier in IgM paraproteinemic neuropathy: a clinicopathologic assessment. Acta Neuropathol. 1998;95(2):184-192. doi. 10.1007/s004010050785.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004010050785</ArticleId><ArticleId IdType="pubmed">9498055</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe M, Sano Y, Maeda T, et al. . Establishment and characterization of human peripheral nerve microvascular endothelial cell lines: a new in vitro blood-nerve barrier (BNB) model. Cell Struct Funct. 2012;37(2):89-100. doi. 10.1247/csf.11042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1247/csf.11042</ArticleId><ArticleId IdType="pubmed">22672995</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu F, Takeshita Y, Sano Y, et al. . GRP78 antibodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndrome. Brain. 2019;142(8):2253-2264. doi. 10.1093/brain/awz168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz168</ArticleId><ArticleId IdType="pubmed">31236596</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohno M, Kobayashi S, Yamamoto T, et al. . Enhancing calmodulin binding to cardiac ryanodine receptor completely inhibits pressure-overload induced hypertrophic signaling. Commun Biol. 2020;3(1):714. doi. 10.1038/s42003-020-01443-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-020-01443-w</ArticleId><ArticleId IdType="pmc">PMC7691336</ArticleId><ArticleId IdType="pubmed">33244105</ArticleId></ArticleIdList></Reference><Reference><Citation>Stork ACJ, Rijkers GT, Vlam L, et al. . Serum cytokine patterns in immunoglobulin m monoclonal gammopathy-associated polyneuropathy. Muscle Nerve. 2019;59(6):694-698. doi. 10.1002/mus.26462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26462</ArticleId><ArticleId IdType="pubmed">30847948</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu ZG. Molecular mechanism of TNF signaling and beyond. Cell Res. 2005;15(1):24-27. doi. 10.1038/sj.cr.7290259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cr.7290259</ArticleId><ArticleId IdType="pubmed">15686622</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan W, Kastin AJ. Tumor necrosis factor and stroke: role of the blood-brain barrier. Prog Neurobiol. 2007;83(6):363-374. doi. 10.1016/j.pneurobio.2007.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2007.07.008</ArticleId><ArticleId IdType="pmc">PMC2190541</ArticleId><ArticleId IdType="pubmed">17913328</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Zhang L, Joo D, Sun SC. NF-&#x3ba;B signaling in inflammation. Signal Transduct Target Ther. 2017;2(1):17023. doi. 10.1038/sigtrans.2017.23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sigtrans.2017.23</ArticleId><ArticleId IdType="pmc">PMC5661633</ArticleId><ArticleId IdType="pubmed">29158945</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong L, Simard MJ, Huot J. Endothelial microRNAs regulating the NF-&#x3ba;B pathway and cell adhesion molecules during inflammation. FASEB J. 2018;32(8):4070-4084. doi. 10.1096/fj.201701536r.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201701536r</ArticleId><ArticleId IdType="pubmed">29565737</ArticleId></ArticleIdList></Reference><Reference><Citation>Mussbacher M, Salzmann M, Brostjan C, et al. . Cell type-specific roles of NF-&#x3ba;B linking inflammation and thrombosis. Front Immunol. 2019;10:85. doi. 10.3389/fimmu.2019.00085.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00085</ArticleId><ArticleId IdType="pmc">PMC6369217</ArticleId><ArticleId IdType="pubmed">30778349</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Yang X, Bian F, et al. . TNF-&#x3b1; promotes early atherosclerosis by increasing transcytosis of LDL across endothelial cells: crosstalk between NF-&#x3ba;B and PPAR-&#x3b3;. J Mol Cel Cardiol. 2014;72:85-94. doi. 10.1016/j.yjmcc.2014.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2014.02.012</ArticleId><ArticleId IdType="pubmed">24594319</ArticleId></ArticleIdList></Reference><Reference><Citation>Dasgupta S, Silva J, Wang G, Yu RK. Sulfoglucuronosyl paragloboside is a ligand for T cell adhesion: regulation of sulfoglucuronosyl paragloboside expression via nuclear factor &#x3ba;B signaling. J Neurosci Res. 2009;87(16):3591-3599. doi. 10.1002/jnr.22153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.22153</ArticleId><ArticleId IdType="pmc">PMC3690938</ArticleId><ArticleId IdType="pubmed">19533738</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu F, Sawai S, Sano Y, et al. . Severity and patterns of blood-nerve barrier breakdown in patients with chronic inflammatory demyelinating polyradiculoneuropathy: correlations with clinical subtypes. PLoS One. 2014;9(8):e104205. doi. 10.1371/journal.pone.0104205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0104205</ArticleId><ArticleId IdType="pmc">PMC4126720</ArticleId><ArticleId IdType="pubmed">25105500</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalakas MC, Rakocevic G, Salajegheh M, et al. . Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol. 2009;65(3):286-293. doi. 10.1002/ana.21577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21577</ArticleId><ArticleId IdType="pubmed">19334068</ArticleId></ArticleIdList></Reference><Reference><Citation>Briani C, Visentin A, Castellani F, Cacciavillani M, Trentin L. The BCL2 inhibitor venetoclax plus rituximab is active in MYD88 wild-type polyneuropathy with anti-MAG antibodies. Neurol Neuroimmunol Neuroinflamm. 2022;9(4):e1181. doi. 10.1212/nxi.0000000000001181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/nxi.0000000000001181</ArticleId><ArticleId IdType="pubmed">35798560</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>